April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.
Category: FACIT Features
CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.